Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Mission Therapeutics has begun Phase 1b dosing of MTX325, an orally bioavailable, brain-penetrant USP30 inhibitor designed to restore mitophagy — the selective clearance of damaged mitochondria — in patients with mild to moderate idiopathic Parkinson's disease. The 36-participant trial across the UK, Europe and Australia will assess safety, tolerability, biomarkers and imaging, with proof-of-mechanism data expected in late 2027. Targeting mitochondrial quality control rather than dopaminergic symptom replacement places this program among the first clinical tests of a core aging mechanism in neurodegeneration.
Oxford Healthspan has released Primeadine GF Spermidine Powder, a mixable gluten-free formulation delivering 1 mg of whole-food spermidine per serving from broken cell wall chlorella, with nobiletin from Shikuwasa citrus peel and curcumin. Spermidine is studied for its role in autophagy, the cellular recycling process that declines with age. The powder format addresses adherence by allowing the dose to be added to food or beverages rather than taken as a tablet.
Oncologist and researcher Siddhartha Mukherjee outlines how cancer care is shifting toward earlier detection and therapies that exploit the metabolic and immune distinctiveness of malignant cells. He notes that second- and third-line therapies in certain cancers now produce genuine extensions of lifespan rather than marginal delays. For longevity, the practical leverage remains in risk reduction and detecting disease while it is still curable.
Chaperone-mediated autophagy, a selective pathway for degrading damaged intracellular proteins, declines with age and this loss corresponds with a higher burden of senescent cells in tissue. Part of the mechanism involves impaired macrophage surveillance, so senescent cells that would normally be recognized and removed persist, contributing to tissue dysfunction and systemic aging.
Prenuvo has opened an imaging biobank of more than 200,000 whole-body MRI scans to over 50 research institutions, accompanied by four initial studies. The largest reported that roughly 7% of 78,000 self-referred individuals had a clinically significant brain abnormality, including aneurysms, infarcts and meningiomas. The data come from a self-selected population, and whether detection of such findings translates into longer healthy life remains unresolved.
Chronic high-fat feeding in rats imprinted a persistent senescence-like state on the liver's regenerative cell population, marked by mitochondrial dysfunction, oxidative stress, inflammatory secretion, and diminished proliferative capacity after injury. The defect persisted in organoids cultured for three passages outside the original metabolic environment, indicating the cells retained the program rather than merely responding to their surroundings. Mitochondria-targeted antioxidant treatment partially restored regenerative function, identifying mitochondrial failure as a modifiable component.
Reviewers in Biology propose SIRT1 functional reserve — the remaining operational flexibility of SIRT1-dependent responses under a defined stress load — as a more meaningful measure than static SIRT1 or NAD+ levels. Total cellular NAD+ obscures compartment-specific availability, and total SIRT1 obscures the accumulation of less functional v2 and v3 isoforms with age, which may account for the modest results of supplementation trials aimed at raising these molecules.
A Lancet Neurology study measuring 130 blood proteins across 2,385 samples from patients receiving lecanemab found that the markers tracking amyloid clearance were largely distinct from those tracking later cognitive decline. Brain-derived tau variants outperformed peripherally produced forms in distinguishing treated patients from untreated controls. The findings point toward multi-marker blood profiling as a route to understanding why identical diagnoses and identical therapies produce divergent outcomes.
GlobalData projects Alzheimer's drug sales across eight major markets to rise from $2.4 billion in 2023 to $14.7 billion by 2033, with disease-modifying antibodies against amyloid-beta accounting for nearly two-thirds of that spending. Much of the growth reflects an aging population and high drug pricing rather than substantially improved patient outcomes, since the leading antibodies slow decline modestly and require infusion infrastructure and repeat MRI monitoring. Subcutaneous and oral formulations under development signal a shift toward delivery models that could reach patients outside specialist centers.
Arvinas presented Phase 1 biomarker data in Seoul on ARV-102, an oral compound that tags the LRRK2 protein for destruction by the cell's own disposal machinery rather than blocking its activity. In 24 people with Parkinson's dosed for 28 days, reductions in LRRK2 tracked with improved saccadic eye movements, lower cerebrospinal fluid markers of endolysosomal dysfunction and neuroinflammation, and higher markers of synaptic integrity. The trial was not designed to measure clinical benefit, and the sample remains small.
Boehringer Ingelheim has expanded its research collaboration with Variant Bio from kidney disease into cardiovascular disease, in an agreement with a potential total value above $250 million. Variant Bio's Inference platform combines statistical genetics, machine learning and large language models to screen genetic data from diverse global populations for drug targets with human genetic support. No specific targets have been named and no resulting compound is described as being in clinical testing.
In a 16-week single-arm trial of 25 adults with type 2 diabetes, an ad libitum low-fat plant-based diet produced a spontaneous 346 kcal/day reduction in intake, 6 kg of weight loss, a 33% drop in liver fat, and substantial declines in visceral fat, fasting glucose, insulin, and LDL cholesterol. Skin advanced glycation end-products also fell, and several participants reduced or discontinued metformin. The absence of a control group and reliance on self-reported intake limit causal interpretation, but the metabolic shifts align with ectopic fat as a driver of insulin resistance.